Deckers Outdoor Corp. 10-K Summary (Fiscal Year Ended Dec 31, 2000)
Business Context and Reporting Period
This Annual Report covers the fiscal year ended December 31, 2000. Deckers Outdoor Corporation designs and markets innovative footwear under three primary brands: Teva (high-performance sandals and outdoor footwear), Simple (casual lifestyle shoes), and Ugg (sheepskin boots). The Company operates as a global lifestyle brand builder, sourcing products primarily from independent manufacturers in the Far East, Australia, and New Zealand. In 2000, the Company sold approximately 4.27 million pairs of footwear.
Key Financial Metrics
| Metric | 2000 | 1999 | Change |
|---|---|---|---|
| Net Sales | $113.74 million | $111.10 million | +2.4% |
| Gross Profit | $50.20 million | $45.05 million | +11.4% |
| Gross Margin | 44.1% | 40.5% | +3.6 pts |
| Operating Income | $12.63 million | $6.75 million | +87.1% |
| Net Earnings | $7.02 million | $2.88 million | +143.2% |
| Diluted EPS | $0.74 | $0.32 | +131.3% |
| Cash from Operations | $14.65 million | $18.21 million | -19.5% |
| Working Capital | $40.48 million | $38.66 million | +4.7% |
| Long-Term Debt | $0.45 million | $6.28 million | -92.8% |
Liquidity: As of December 31, 2000, the Company held $9.06 million in cash and cash equivalents. It maintains a $50 million revolving credit facility with $10.53 million available (no outstanding borrowings, $2.21 million in letters of credit).
Material Changes vs. Prior Period
- Revenue Mix: Teva sales decreased 1.5% to $79.73 million due to reduced sales in athletic retail channels, though this was offset by international growth and new hiking models. Ugg sales surged 26.5% to $15.31 million, driven by early cold weather, new models, and high-profile media exposure (Oprah Winfrey Show). Simple sales grew 5.1% to $16.33 million.
- Profitability: Gross margin improved significantly to 44.1% from 40.5%, attributed to better inventory management, reduced sales returns, and improved pricing/sourcing. Operating expenses decreased as a percentage of sales (33.0% vs 34.5%) due to the non-recurrence of 1999 severance and litigation charges.
- Debt Reduction: The Company significantly reduced its debt load, paying down the majority of its revolving credit facility balance from $5.83 million in 1999 to zero in 2000.
- Unusual Items: The Company recorded a $400,000 charge to SG&A expenses to accrue for potential exposure to European anti-dumping duties on Teva products imported from China.
Guidance, Outlook, and Risks
2001 Outlook: Management expects 2001 net sales to range from $100 million to $105 million and diluted EPS to range from $0.65 to $0.70. Sales and earnings are expected to be down in the first half of 2001 compared to 2000, with year-over-year gains anticipated in the fourth quarter driven by the Ugg brand and new Spring 2002 product introductions.
Key Risks and Contingencies:
- Teva License: The Company's license for the Teva brand (70.1% of 2000 sales) expires in 2004 unless minimum sales levels are met. Failure to meet these levels would result in the loss of the license. The Company holds an option to acquire Teva assets, exercisable through 2003, with a price formula tied to sales (minimum $61.6 million plus $1.6 million).
- Legal Proceedings: The Company is appealing a $1.785 million jury verdict from 1999 regarding trade secret allegations (Molly Strong-Butts case). Management believes the claim is without merit.
- Foreign Operations: Virtually all products are manufactured overseas (primarily China). Risks include anti-dumping duties, currency fluctuations, and supply chain disruptions. The Company is actively sourcing alternatives to mitigate European anti-dumping risks.
- Seasonality: Sales are highly seasonal, with Teva peaking in Q1/Q2 and Ugg peaking in Q4.
Investor Verification Checklist
- Teva License Status: Verify current sales performance against the minimum thresholds required to renew the Teva license beyond 2004.
- Acquisition Option: Assess the likelihood and financing terms of the Company exercising its option to acquire the Teva brand assets.
- Legal Exposure: Monitor the status of the appeal regarding the $1.785 million Molly Strong-Butts verdict.
- European Duties: Confirm the final determination by Dutch Customs regarding the 49.2% anti-dumping duties and the effectiveness of alternative sourcing strategies.
- Ugg Growth Sustainability: Evaluate whether the 26.5% growth in Ugg sales is sustainable given the impact of weather and media exposure.